The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II–III and metastatic breast cancers

Karen S. Anderson(Institute for Biodiversity), Beth Overmoyer(Harvard University)
Breast Cancer Research and Treatment
April 28, 2022
10.1007/s10549-022-06562-y
Cited by 23

Related Papers

The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors
|Journal of Clinical Investigation|2011|928
Classifying the evolutionary and ecological features of neoplasms
|Nature reviews. Cancer|2017|455
Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes
|Nature Communications|2019|196
Oral Human Papillomavirus (HPV) Infection in HPV-Positive Patients With Oropharyngeal Cancer and Their Partners
|Journal of Clinical Oncology|2014|161
Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer
|npj Breast Cancer|2018|150